Company · RHHBY
Roche (Genentech)
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
95
49 still marketed
Novel approvals
51
Approvals since 2021
85
Originals and new uses
Phase 3 trials
642
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Gazyva new use Priority reviewNov 13, 2026
- Enspryng new use Priority reviewOct 15, 2026
- Tecentriq new use Priority reviewOct 8, 2026
- Tecentriq Hybreza new use Priority reviewOct 8, 2026
- Gazyva new use Priority reviewOrphanSep 25, 2026
- Alecensa new use OrphanJun 11, 2026
- Tecentriq new use Priority reviewMay 15, 2026
- Tecentriq Hybreza new use Priority reviewMay 15, 2026
- Ocrevus new use Priority reviewMay 8, 2026
- Perjeta new use Apr 23, 2026
Drugs in development (58)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
- LHRH AgonistPhase 36 trials
Roche (Genentech) · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- bypassing agentsClotting factor concentrates, CFCPhase 33 trials
Sanofi · Hemophilia, Von Willebrand Disease, Type 3
- LHRHLuteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone AgonistsPhase 33 trials
AstraZeneca · ER-Positive HER2-Negative Breast Cancer, Ovarian Cancer
- PegozaferminBIO89-100Phase 33 trials
Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia
- PrasinezumabRO7046015, PRX002Phase 33 trials
Roche (Genentech) · Parkinson's Disease, Parkinsons Disease
- RO7204239Phase 33 trials
Roche (Genentech) · Obesity, Overweight, Overweight With One Weight Related Comorbidity
- AAV2-hRPE65v2voretigene neparvovec-rzylPhase 32 trials
Roche (Genentech) · Leber Congenital Amaurosis, Inherited Retinal Dystrophy Due to RPE65 Mutations
- BL-8040Phase 32 trials
BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma
- CDK4Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Advanced ER+/HER2- Breast Cancer, Breast Cancer
- EmactuzumabPhase 32 trials
Roche (Genentech) · Cancer, TGCT
- NXT007Zemocimig, RO7589655Phase 32 trials
Roche (Genentech) · Hemophilia A
- RituxumabPhase 32 trials
Roche (Genentech) · Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
- TPST-1120Phase 32 trials
Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)
- VamikibartRO7200220Phase 32 trials
Roche (Genentech) · Uveitic Macular Edema
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06419374 · 1,800 participants (planned) · Start May 24, 2024 · Primary completion Jun 30, 2028
Drug: Pegozafermin; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Sites: Birmingham, Alabama; Homewood, Alabama; Chandler, Arizona · 335 sites in all
- A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07717411 · 1,600 participants (planned) · Start Oct 2, 2026 · Primary completion Jul 30, 2032
Drug: Trontinemab; Placebo · For: Alzheimer's Disease
Sites: Irvine, California; Long Beach, California; Los Angeles, California · 72 sites in all
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07827573 · 1,500 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: Giredestrant · For: Early Breast Cancer; Estrogen Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer
Sites: Salem, Oregon; Richmond, Virginia; Montreal, Canada · 4 sites in all
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06318169 · 1,350 participants (planned) · Start Mar 13, 2024 · Primary completion Feb 2029
Drug: Pegozafermin · For: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 370 sites in all
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household ContactsPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06094010 · 1,100 participants (planned) · Start Nov 22, 2023 · Primary completion May 11, 2027
Drug: Baloxavir Marboxil · For: Influenza
Sites: Birmingham, Alabama; Harrisburg, Arkansas; Miami, Florida · 52 sites in all
- Extension Study for the Port Delivery System With Ranibizumab (Portal)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03683251 · 1,000 participants (planned) · Start Sep 20, 2018 · Primary completion Dec 31, 2029
Drug: PDS Implant with Ranibizumab 100 mg/mL · For: Neovascular Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 165 sites in all
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07174310 · 900 participants (planned) · Start Nov 24, 2025 · Primary completion Jun 30, 2029
Drug: Prasinezumab; Placebo · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fullerton, California · 192 sites in all
- RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositivePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07413939 · 650 participants (planned) · Start May 21, 2026 · Primary completion May 1, 2029
Drug: RO7771950; Tucatinib and 2 more · For: HER2-positive Breast Cancer
Sites: Huntsville, Alabama; Gilbert, Arizona; Clovis, California · 219 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06793215 · 600 participants (planned) · Start Oct 24, 2025 · Primary completion Nov 30, 2028
Drug: Divarasib; Pembrolizumab and 3 more · For: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
Sites: Anchorage, Alaska; Goodyear, Arizona; Clovis, California · 299 sites in all
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06819878 · 600 participants (planned) · Start Mar 17, 2025 · Primary completion Dec 31, 2028
Drug: Afimkibart; Placebo · For: Moderately to Severely Active Crohns Disease
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 375 sites in all
Marketed drugs (49)
Newest FDA action first.
- Gazyva Obinutuzumab · 2013
- Enspryng Satralizumab · 2020
- Tecentriq Atezolizumab · 2016
- Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · 2024
- Rozlytrek Entrectinib · 2019
- Rozlytrek Entrectinib · 2023
- Evrysdi Risdiplam · 2025
- Evrysdi Risdiplam · 2020
- Cotellic Cobimetinib Fumarate · 2015
- Zelboraf Vemurafenib · 2011
- Alecensa Alectinib Hydrochloride · 2015
- Xolair Omalizumab · 2003
- Cellcept Mycophenolate Mofetil · 1995
- Cellcept Mycophenolate Mofetil · 1997
- Cellcept Mycophenolate Mofetil · 1998
- Cellcept Mycophenolate Mofetil Hydrochloride · 1998
- Columvi Glofitamab-Gxbm · 2023
- Lunsumio Velo Mosunetuzumab-Axgb · 2022
- Ocrevus Zunovo Ocrelizumab and Hyaluronidase-Ocsq · 2024
- Herceptin Trastuzumab · 1998
- Phesgo Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf · 2020
- Herceptin Hylecta Trastuzumab and Hyaluronidase-Oysk · 2019
- Ocrevus Ocrelizumab · 2017
- Perjeta Pertuzumab · 2012
- Itovebi Inavolisib · 2024
- Vabysmo Faricimab-Svoa · 2022
- Kadcyla Ado-Trastuzumab Emtansine · 2013
- Polivy Polatuzumab Vedotin-Piiq · 2019
- Actemra Tocilizumab · 2010
- Actemra Tocilizumab · 2013
- Susvimo Ranibizumab · 2021
- Nutropin Aq Pen Somatropin · 1995
- Hemlibra Emicizumab · 2017
- Xofluza Baloxavir Marboxil · 2022
- Xofluza Baloxavir Marboxil · 2018
- Piasky Crovalimab-Akkz · 2024
- Tnkase Tenecteplase · 2000
- Lucentis Ranibizumab · 2006
- Pulmozyme Dornase Alfa · 1993
- Erivedge Vismodegib · 2012
- Avastin Bevacizumab · 2004
- Activase Alteplase · 1987
- Rituxan Rituximab · 1997
- Tamiflu Oseltamivir Phosphate · 2000
- Rituxan Hycela Rituximab, Hyaluronidase (Human Recombinant) · 2017
- Rozlytrek Entrectinib · 2019
- Tamiflu Oseltamivir Phosphate · 1999
- Nutropin Somatropin [Rdna Origin] · 1994
- Tecentriq Atezolizumab · 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.